Aurobindo Pharma, a leading player in the active pharmaceutical ingredient and generic market, has issued a statement clarifying that reports of buying out Prague-based generic drugmaker Zentiva are ‘premature’, and no binding agreement has been made by company, according to a company filing issued on August 20.
Earlier today, The Economic Times had reported citing people familiar with the development that the pharma company is the frontrunner to acquire Zentiva from Advent International for $5-5.5 billion, or Rs 43,500-47,900 crore.
The shares of Aurobindo Pharma recovered from early lows soon after the statement was made public, though still lower by 3 percent in the trading session. So far in 2025, Aurobindo Pharma’s stock has declined by 21 percent, compared with a 2 percent modest rise in the benchmark Nifty 50 index.
“…at present, no binding agreement or definitive decision has been made by the Board of Directors of the Company in relation to the transaction referred to in the said article(s). Accordingly, the said news item is premature and should not be relied upon,” the company filing said.
Aurobindo Pharma added that it ‘regularly explores’ various strategic opportunities, including potential acquisitions and partnerships, which can enhance shareholder value. “In the event of any definitive development requiring disclosure under the SEBI Listing Regulations, the Company will promptly make the necessary and timely announcements to the stock exchanges in accordance with applicable regulatory requirements,” Aurobindo Pharma added.
